Ensysce Biosciences, Inc. (ENSC) Form 8-K — May 15, 2026
Ensysce Biosciences reported a Q1 2026 net loss of $3.6 million, widening from $1.9 million in the prior year, driven by increased R&D spend of $3.3 million for its Phase 3 PF614 trial. Cash reserves dropped to $0.7 million at quarter-end, though the company closed a $2.0 million financing tranche in April under a $20 million commitment. Clinically, the company secured IRB approval for the final stage of its PF614-MPAR-102 overdose protection study and published peer-reviewed data validating its MPAR technology. These milestones support its Breakthrough Therapy designation and advance its lead opioid candidate.
Key figures
- Revenue
- 0
- Total Debt
- 245849
- Total Assets
- 2167803
- Cash Position
- 745482
- Q1 ga expenses
- 1176348
- Q1 rd expenses
- 3346881
- Federal grants q1
- 960999
- Recent financing tranche
- 2000000
- Total financing commitment
- 20000000
Price after filing
Close on the filing date to close N calendar days later (from $0.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.